SARS-CoV-2 multi-epitope subunit vaccine proof-of-concept derived from the insilico study with protein expression in Escherichia coli BL21

Keyphrases

• Protein Expression 100%
• In Silico Study 100%
• Escherichia Coli BL21 100%
• Expression in Escherichia Coli 100%
• COVID-19 100%
• Multi-epitope Vaccine 100%
• Escherichia Coli 66%
• E. Coli BL21 66%
• Multi-epitope 66%
• SARS-CoV-2 Vaccine 66%
• Recombinant Vaccine 66%
• Vaccine Antigen 33%
• High Protein 33%
• Epitope 33%
• Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 33%
• Protein Bands 33%
• In Silico 33%
• Recombinant 33%
• Bioinformatics 33%
• Gene Cloning 33%
• T Cell Response 33%
• Tracker 33%
• Vaccine Development 33%
• Immunoinformatics 33%
• COVID-19 Pandemic 33%
• Plasmid Vector 33%
• Codon Optimization 33%
• SARS-CoV-2 Proteins 33%
• Immunoinformatics Tools 33%
• SARS-CoV-2 Epitopes 33%
• RNA Structure 33%
• Vaccine Protein 33%
• Linker Sequence 33%
• Rare Codon 33%
• Flexible Linker 33%
• Ribosomal Binding Site 33%
• Binding Site Analysis 33%
• Epitope Peptide 33%
• Plasmid Design 33%
• Codon Usage Analysis 33%
• Protein Subunit Vaccine 33%
• HLA-I 33%
• HLA-II 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Protein Vaccine 16%